Why the study?
Doxorubicin has a wide antitumor spectrum but adverse cardiotoxicity leading to heart failure, while exercise rehabilitation is recognized as a cornerstone of cardiac rehabilitation.
Does Urantide and exercise training prevent doxorubicin-induced cardiotoxicity in a rat model?
Does Urantide and exercise training prevent doxorubicin-induced cardiotoxicity in a rat model?
Urantide and exercise training mitigate doxorubicin-induced cardiotoxicity and apoptosis in rats by downregulating the p38 MAPK signaling pathway.
Answers are grounded in this paper and cite their sources.
Urantide plus exercise may attenuate doxorubicin cardiotoxicity in preclinical models; hypothesis-generating for clinical translation in cancer patients.
Doxorubicin (DOX) has a wide antitumor spectrum, but its adverse cardiotoxicity may lead to heart failure. Urotensin II (UⅡ) is the most potent vasoconstrictor in mammals. It plays a role by activating the UII receptor (UT), the orphan G protein-coupled receptor (GPR14), collectively referred to as the UII/UT system. In the new version of "Chinese expert consensus on cardiac rehabilitation of chronic heart failure," it is pointed out that exercise rehabilitation is the cornerstone of cardiac rehabilitation. In this study, in vitro and in vivo assessments were performed using DOX-treated H9C2 cells and rats. It was found that the UT antagonist Urantide and exercise training improved DOX-induced cardiac insufficiency, reduced DOX-induced cardiomyocyte apoptosis, improved the structural disorder of myocardial fibers, and inhibited DOX-induced myocardial fibrosis. Further studies showed that Urantide alleviated DOX-induced cardiotoxicity by downregulating the expression levels of the p38 mitogen-activated protein kinase signaling pathway.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2022) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: